Browse by People


Up a level
Export as [feed] RSS [feed] RSS 2.0 Short Author List
Number of items: 26.


Burnett, Alan K, Das Gupta, Emma, Knapper, Steve, Khwaja, Asim, Sweeney, Marion, Kjeldsen, Lars, Hawkins, Timothy, Betteridge, Sophie E, Cahalin, Paul, Clark, Richard E ORCID: 0000-0002-1261-3299
et al (show 3 more authors) (2018) Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial. HAEMATOLOGICA, 103 (10). 1654 - 1661.


Clark, Richard E ORCID: 0000-0002-1261-3299, Apperley, Jane F, Copland, Mhairi and Cicconi, Silvia
(2021) Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression. BLOOD ADVANCES, 5 (4). 1102 - 1109.


Kinstrie, Ross, Horne, Gillian A, Morrison, Heather, Irvine, David, Munje, Chinmay, Castaneda, Eduardo Gomez, Moka, Hothri A, Dunn, Karen, Cassels, Jennifer E, Parry, Narissa
et al (show 6 more authors) (2020) CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. LEUKEMIA, 34 (6). 1613 - 1625.


Lucas, Claire M ORCID: 0000-0001-6674-7535, Scott, Laura J, Carmell, Natasha, Holcroft, Alison K, Hills, Robert K, Burnett, Alan K and Clark, Richard E ORCID: 0000-0002-1261-3299
(2018) CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML. Blood Advances, 2 (9). 964 - 968.


Austin, James A, Jenkins, Rosalind E ORCID: 0000-0002-3730-1136, Austin, Gemma M, Glenn, Mark A, Dunn, Karen, Scott, Laura, Lucas, Claire M and Clark, Richard E ORCID: 0000-0002-1261-3299
(2019) Cancerous inhibitor of protein phosphatase 2A (CIP2A) modifies energy metabolism via 5 ' AMP-activated protein kinase signalling in malignant cells. BIOCHEMICAL JOURNAL, 476. 2255 - 2269.


Clark, Richard E ORCID: 0000-0002-1261-3299, Polydoros, Fotios ORCID: 0000-0001-5181-6817, Apperley, Jane F, Milojkovic, Dragana, Pocock, Christopher, Smith, Graeme, Byrne, Jenny L, de lavallade, Hugues, O'Brien, Stephen G, Coffey, Tony
et al (show 2 more authors) (2017) De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. The Lancet Haematology, 4 (7). E310 - E316.


Clark, Richard E ORCID: 0000-0002-1261-3299, Polydoros, Fotios, Apperley, Jane F, Milojkovic, Dragana, Rothwell, Katherine, Pocock, Christopher, Byrne, Jennifer, de lavallade, Hugues, Osborne, Wendy, Robinson, Lisa
et al (show 4 more authors) (2019) De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. The Lancet Haematology, 6 (7). E375 - E383.


Burnett, Alan K, Russell, Nigel H, Hills, Robert K, Knapper, Stephen, Freeman, Sylvie, Huntly, Brian, Clark, Richard E ORCID: 0000-0002-1261-3299, Thomas, Ian F, Kjeldsen, Lars, McMullin, Mary Frances
et al (show 3 more authors) (2020) Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. JCO2001170 - JCO2001170.


Makela, Eleonora, Pavic, Karolina, Varila, Taru, Salmenniemi, Urpu, Loyttyniemi, Eliisa, Nagelli, Srikar G, Ammunet, Tea, Kahari, Veli-Matti, Clark, Richard E ORCID: 0000-0002-1261-3299, Elo, Laura L
et al (show 4 more authors) (2021) Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias. CLINICAL CANCER RESEARCH, 27 (10). 2848 - 2860.


Pfirrmann, Markus, Clark, Richard E ORCID: 0000-0002-1261-3299, Prejzner, Witold, Lauseker, Michael, Baccarani, Michele, Saussele, Susanne, Guilhot, Francois, Heibl, Sonja, Hehlmann, Rudiger, Faber, Edgar
et al (show 20 more authors) (2020) The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. LEUKEMIA, 34 (8). 2138 - 2149.


Martin, Antony P ORCID: 0000-0003-4383-6038, Richards, Sarah, Haycox, Alan ORCID: 0000-0001-6659-4866, Houten, Rachel ORCID: 0000-0002-4315-7732, McLeod, Claire, Braithwaite, Barbara, Clark, Jack O, Bell, Joanne and Clark, Richard E ORCID: 0000-0002-1261-3299
(2016) Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial. JOURNAL OF CLINICAL APHERESIS, 31 (5). 434 - 442.


Tidd, David M, Giles, Richard V, Broughton, Caroline M and Clark, Richard E
(2001) Expression of c-myc is not critical for cell proliferation in established human leukemia lines. BMC Molecular Biology, 2.


Kinstrie, Ross, Karamitros, Dimitris, Goardon, Nicolas, Morrison, Heather, Hamblin, Mike, Robinson, Lisa, Clark, Richard E ORCID: 0000-0002-1261-3299, Copland, Mhairi and Vyas, Paresh
(2016) Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia. BLOOD ADVANCES, 1 (3). 160 - 169.


Kantarjian, Hagop M, Hughes, Timothy P, Larson, Richard A, Kim, Dong-Wook, Issaragrisil, Surapol, le Coutre, Philipp, Etienne, Gabriel, Boquimpani, Carla, Pasquini, Ricardo, Clark, Richard E ORCID: 0000-0002-1261-3299
et al (show 11 more authors) (2021) Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia.


Gottschalk, Andrea, Glauche, Ingmar, Cicconi, Silvia ORCID: 0000-0001-5507-6203, Clark, Richard E ORCID: 0000-0002-1261-3299 and Roeder, Ingo
(2020) Molecular dynamics during reduction of TKI dose reliably identify molecular recurrence after treatment cessation in CML. Blood.


Lauseker, Michael, Bachl, Katharina, Turkina, Anna, Faber, Edgar, Prejzner, Witold, Olsson-Stromberg, Ulla, Baccarani, Michele, Lomaia, Elza, Zackova, Daniela, Ossenkoppele, Gert
et al (show 12 more authors) (2019) Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. AMERICAN JOURNAL OF HEMATOLOGY, 94 (11). 1236 - 1243.


Milojkovic, Dragana, Cross, Nicholas CP, Ali, Sahra, Byrne, Jenny, Campbell, Gavin, Dignan, Fiona L, Drummond, Mark, Huntly, Brian, Marshall, Scott, McMullin, Mary Frances
et al (show 12 more authors) (2021) Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. BRITISH JOURNAL OF HAEMATOLOGY, 192 (1). 62 - 74.


Cortes, Jorge E, Candoni, Anna, Clark, Richard E ORCID: 0000-0002-1261-3299, Leber, Brian, Montesinos, Pau, Vyas, Paresh, Zeidan, Amer M and Heuser, Michael
(2020) Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review. Leukemia and Lymphoma, 61 (14). 3287 - 3305.


Davies, Andrea, Rodriguez-Vicente, Ana Eugenia, Austin, Gemma, Loaiza, Sandra, Foroni, Letizia, Clark, Richard E ORCID: 0000-0002-1261-3299 and Pirmohamed, Munir ORCID: 0000-0002-7534-7266
(2020) Serotonin re-uptake transporter gene polymorphisms are associated with imatinib-induced diarrhoea in chronic myeloid leukaemia patients. Scientific reports, 10 (1).


Mitchell, Rebecca, Hopcroft, Lisa EM, Baquero, Pablo, Allan, Elaine K, Hewit, Kay, James, Daniel, Hamilton, Graham, Mukhopadhyay, Arunima, O'Prey, Jim, Hair, Alan
et al (show 14 more authors) (2018) Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 110 (5). 467 - 478.


Clark, Richard E ORCID: 0000-0002-1261-3299
(2019) Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 14 (6). 507 - 514.


Clark, Richard E ORCID: 0000-0002-1261-3299, Basabrain, Ammar A, Austin, Gemma M, Holcroft, Alison K, Loaiza, Sandra, Apperley, Jane F, Law, Christopher, Scott, Laura, Parry, Alexandra D, Bonnett, Laura ORCID: 0000-0002-6981-9212
et al (show 1 more authors) (2021) Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia. CANCERS, 13 (9).


Clark, Richard E ORCID: 0000-0002-1261-3299
(2020) The chronic myeloid leukaemia story in the United Kingdom since 1960. BRITISH JOURNAL OF HAEMATOLOGY, 191 (4). 521 - 526.


Austin, Gemma M, Knight, Katy, Bell, Joanne, Carter, Anthony, Heartin, Earnest, Watson, David, Foroni, Letizia, Christmas, Stephen E, Polydoros, Fotios and Clark, Richard E ORCID: 0000-0002-1261-3299
(2019) The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trial. BRITISH JOURNAL OF HAEMATOLOGY, 185 (4). 791 - 793.


Ferguson, Paul, Hills, Robert K, Grech, Angela, Betteridge, Sophie, Kjeldsen, Lars, Dennis, Michael, Vyas, Paresh, Goldstone, Anthony H, Milligan, Donald, Clark, Richard E ORCID: 0000-0002-1261-3299
et al (show 3 more authors) (2016) An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation. HAEMATOLOGICA, 101 (11). 1351 - 1358.


Dennis, Mike, Burnett, Alan, Hills, Robert, Thomas, Ian, Ariti, Cono, Severinsen, Marianne T, Hemmaway, Claire, Greaves, Paul, Clark, Richard E ORCID: 0000-0002-1261-3299, Copland, Mhairi
et al (show 3 more authors) (2021) A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial. BRITISH JOURNAL OF HAEMATOLOGY, 194 (2). 298 - 308.

This list was generated on Fri Nov 26 11:38:10 2021 GMT.